Ampion is based on an immunomodulatory molecule derived from the N-terminus of the human serum albumin. The trial will evaluate its intravenous application as a treatment for patients with COVID-19 who are on supplemental oxygen.

Ampio begins COVID-19 phase I clinical trial for immunotherapy
Ampio Pharmaceuticals will begin a phase I clinical trial to evaluate its Ampion drug candidate for treatment of COVID-19 patients who are on supplemental...

Immunic begins phase II immunotherapy for COVID-19
Immunic has enrolled the first COVID-19 patients in a phase II clinical trial of IMU-838, a selective oral dihydroorotate dehydrogenase (DHODH) inhibitor.